Corey J. Langer
Oncology
51 N. 39th Street
Pavilion For Advanced Care, First Floor
Philadelphia, PA 19104
Pavilion For Advanced Care, First Floor
Philadelphia, PA 19104
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 195 publications
EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer.
Journal: JCO precision oncology
Published: July 15, 2026
Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461].
Journal: The journal of liquid biopsy
Published: June 29, 2026
Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC.
Journal: Clinical lung cancer
Published: May 19, 2026
The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing.
Journal: The journal of liquid biopsy
Published: February 08, 2026
Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: February 06, 2026
Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study.
Journal: Frontiers in oncology
Published: January 25, 2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 04, 2025
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 11, 2025
Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy.
Journal: American journal of clinical oncology
Published: May 25, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 15, 2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.
Journal: The Lancet. Oncology
Published: February 28, 2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Journal: Clinical lung cancer
Published: February 07, 2025
Last Updated: 09/26/2026